South Africa approved a twice-yearly injectable medication to prevent HIV-1 transmission, becoming the first African nation to authorize the treatment. The regulatory authority cleared Lenacapavir 464mg solution for use on Monday, Oct. 21, marking a significant development for a country with high infection rates.
The medication is administered under the skin every 6 months and is indicated for adults and adolescents weighing at least 35 kilograms. Authorities recommend combining the injections with safer sexual practices for maximum protection. The formula received approval from American regulators and European health agencies under different commercial names before South African clearance.
Chief executive Boitumelo Semete-Makokotlela described the authorization as transformative for public health efforts. The antiviral represents the most effective prevention method available for blocking HIV-1 infection when used as pre-exposure prophylaxis.
The medication is administered under the skin every 6 months and is indicated for adults and adolescents weighing at least 35 kilograms. Authorities recommend combining the injections with safer sexual practices for maximum protection. The formula received approval from American regulators and European health agencies under different commercial names before South African clearance.
Chief executive Boitumelo Semete-Makokotlela described the authorization as transformative for public health efforts. The antiviral represents the most effective prevention method available for blocking HIV-1 infection when used as pre-exposure prophylaxis.
